MACCEROL
D3
For the use of a Registered Medical
Practitioner or a Hospital or a Laboratory only
Abbreviated Prescribing information
for MACCEROL D3 (Cholecalciferol 60,000 IU Chewable Tablets)
[Please refer the complete
prescribing information available at www.macnispharma.com]
PHARMACOLOGICAL
PROPERTIES: Cholecalciferol is the naturally occurring form of vitamin D. It is
produced from 7- dehydrocholesterol, a sterol present in mammalian skin, by
ultraviolet irradiation.
INDICATION:
Vitamin D compounds are used in the treatment and prevention of vitamin D
deficiency states and hypocalcaemia in disorders such as hypoparathyroidism and
secondary hyperparathyroidism.
DOSAGE
AND ADMINISTRATION: A dose of 400 units daily is generally sufficient in adults
for the prevention of simple deficiency states; 800 units daily is recommended
in those whose exposure to sunlight is limited, in those whose diet is
deficient in vitamin D, and in housebound or institutionalized elderly people.
Deficiency due to malabsorption states or liver disease often requires higher
doses for treatment, of up to 40 000 units daily. Doses of up to 200 000 units
daily may be used in the treatment of hypocalcaemia due to
hypoparathyroidism.
CONTRAINDICATION:
Contraindicated in the patient known to be hypersensitive (allergic) to vitamin
D and other ingredients, in patients with hypercalcemia, malabsorption
syndrome, abnormal sensitivity to the toxic effects of vitamin D, and
hypervitaminosis D.
WARNINGS
& PRECAUTIONS: Used with cautions in hypersensitivity to vitamin D, in
infants with idiopathic hypercalcemia, patients with hypercalcaemia, renal
impairment or calculi, or heart disease. Plasma phosphate concentrations should
be controlled. Plasma-calcium concentration monitored at regular intervals,
especially initially or if symptoms suggest toxicity. Similar monitoring is
recommended in infants if they are breast fed by mothers receiving
pharmacological doses of vitamin D. Keep out of the reach of children.
DRUG
INTERACTION: Thiazide diuretics, calcium, or phosphate, carbamazepine,
phenobarbital, phenytoin, primidone, rifampicin and isoniazid, corticosteroids,
ketoconazole.
ADVERSE
REACTIONS: Hyperphosphataemia or hypercalcaemia, hypercalciuria, ectopic
calcification, renal and cardiovascular damage, anorexia, lassitude, nausea and
vomiting, constipation or diarrhoea, polyuria, nocturia, sweating, headache,
somnolence, and vertigo, skin irritation or contact dermatitis,
hypersensitivity reaction, muscle weakness, apathy, bone pain, proteinuria,
hypertension, and cardiac arrhythmias, impairment of renal function with
polyuria, polydipsia, reversible azotemia, nephrocalcinosis, generalized
vascular calcification, mental retardation, widespread calcification, bone
demineralization (osteoporosis), mild acidosis, anemia and weight loss.
MARKETED
BY:
MACNIS PHARMACEUTICALS
J3/31 A-3,3rd
Floor,Khiri Extension.
Malviya Nagar,New Delhi-17
Visit us at: www.macnispharma.com
Reach us at: info@macnispharma.com